LEVOTHYROXINE SODIUM- levothyroxine sodium tablet Blenheim Pharmacal, Inc.

Levothyroxine Sodium Tablets, USP

CLINICAL PHARMACOLOGY

Thyroid hormone synthesis and secretion is regulated by the hypothalamic-pituitary-thyroid axis. Thyrotropin-releasing hormone (TRH) released from the hypothalamus stimulates secretion of thyrotropin-stimulating hormone, TSH, from the anterior pituitary. TSH, in turn, is the physiologic stimulus for the synthesis and secretion of thyroid hormones, L-thyroxine (T₄) and L-triiodothyronine (T₃), by the thyroid gland. Circulating serum T₃ and T₄ levels exert a feedback effect on both TRH and TSH secretion. When serum T₃ and T₄ levels increase, TRH and TSH secretion decrease. When thyroid hormone levels decrease, TRH and TSH secretion increase.

The mechanisms by which thyroid hormones exert their physiologic actions are not completely understood, but it is thought that their principal effects are exerted through control of DNA transcription and protein synthesis. T₃ and T₄ diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.

Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone. The metabolic actions of thyroid hormones include augmentation of cellular respiration and thermogenesis, as well as metabolism of proteins, carbohydrates and lipids. The protein anabolic effects of thyroid hormones are essential to normal growth and development.

The physiologic actions of thyroid hormones are produced predominately by T $_3$, the majority of which (approximately 80%) is derived from T $_4$ by deiodination in peripheral tissues.

Levothyroxine, at doses individualized according to patient response, is effective as replacement or supplemental therapy in hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.

Levothyroxine is also effective in the suppression of pituitary TSH secretion in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, Hashimoto's thyroiditis, multinodular goiter and, as adjunctive therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer (see INDICATIONS AND USAGE, PRECAUTIONS, DOSAGE AND ADMINISTRATION).

Pharmacokinetics

Absorption - Absorption of orally administered T ₄ from the gastrointestinal (GI) tract ranges from 40% to 80%. The majority of the levothyroxine dose is absorbed from the jejunum and upper ileum. The relative bioavailability of Levothyroxine Sodium Tablets, USP, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 99%. T ₄ absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybean infant formula. Dietary fiber decreases bioavailability of T ₄. Absorption may also decrease with age. In addition, many drugs and foods affect T ₄ absorption (see **PRECAUTIONS, Drug Interactions** and **Drug-Food Interactions**).

Distribution - Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T ⁴ partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T ⁴

compared to T₃. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins (see **PRECAUTIONS, Drug Interactions** and **Drug-Laboratory Test Interactions**). Thyroid hormones do not readily cross the placental barrier (see **PRECAUTIONS, Pregnancy**).

Metabolism - T₄ is slowly eliminated (see **TABLE 1**). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately eighty-percent of circulating T₃ is derived from peripheral T₄ by monodeiodination. The liver is the major site of degradation for both T₄ and T₃; with T₄ deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T₄ is deiodinated to yield equal amounts of T₃ and reverse T₃ (rT₃). T₃ and rT₃ are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.

Elimination - Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T₄ is eliminated in the stool. Urinary excretion of T₄ decreases with age.

Table 1: Pharmacokinetic Parameters of Thyroid Hormones in EuthyroidPatients

Hormone	Ratio in	Biologic	t _{1/2}	Protein		
	Thyroglobulin	Potency	(days)	Binding (%) ²		
Levothyroxine (T $_4$)	10 - 20	1	6-7 ¹	99.96		
Liothyronine (T ₃)	1	4	≤ 2	99.5		
¹ 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism;						
² Includes TBG, TBPA, and TBA						

INDICATIONS AND USAGE

Levothyroxine sodium is used for the following indications:

Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter.

Pituitary TSH Suppression - In the treatment or prevention of various types of euthyroid goiters (see **WARNINGS** and **PRECAUTIONS**), including thyroid nodules (see **WARNINGS** and **PRECAUTIONS**), subacute or chronic lymphocytic thyroiditis (Hashimoto's thyroiditis), multinodular goiter (see **WARNINGS** and **PRECAUTIONS**), and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

CONTRAINDICATIONS

Levothyroxine is contraindicated in patients with untreated subclinical (suppressed serum TSH level with normal T₃ and T₄ levels) or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction. Levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids (see **PRECAUTIONS**). Levothyroxine Sodium Tablets, USP is contraindicated in patients with hypersensitivity to any of the inactive ingredients in Levothyroxine Sodium Tablets, USP. (See **DESCRIPTION, Inactive Ingredients**).

WARNING: Thyroid hormones, including Levothyroxine Sodium Tablets, USP, either alone or with other therapeutic agents, should not be used for the treatment of obesity for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

Levothyroxine sodium should not be used in the treatment of male or female infertility unless this condition is associated with hypothyroidism.

In patients with nontoxic diffuse goiter or nodular thyroid disease, particularly the elderly or those with underlying cardiovascular disease, levothyroxine sodium therapy is contraindicated if the serum TSH level is already suppressed due to the risk of precipitating overt thyrotoxicosis (see **CONTRAINDICATIONS**). If the serum TSH level is not suppressed, Levothyroxine Sodium Tablets, USP should be used with caution in conjunction with careful monitoring of thyroid function for evidence of hyperthyroidism and clinical monitoring for potential associated adverse cardiovascular signs and symptoms of hyperthyroidism.

PRECAUTIONS

General

Levothyroxine has a narrow therapeutic index. Regardless of the indication for use, careful dosage titration is necessary to avoid the consequences of over- or under-treatment. These consequences include, among others, effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and on glucose and lipid metabolism. Many drugs interact with levothyroxine sodium necessitating adjustments in dosing to maintain therapeutic response (see **Drug Interactions**).

Effects on bone mineral density - In women, long-term levothyroxine sodium therapy has been associated with increased bone resorption, thereby decreasing bone mineral density, especially in postmenopausal women on greater than replacement doses or in women who are receiving suppressive doses of levothyroxine sodium. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase and suppressed serum parathyroid hormone levels. Therefore, it is recommended that patients receiving levothyroxine sodium be given the minimum dose necessary to achieve the desired clinical and biochemical response.

Patients with underlying cardiovas cular disease - Exercise caution when administering levothyroxine to patients with cardiovascular disorders and to the elderly in whom there is an increased risk of occult cardiac disease. In these patients, levothyroxine therapy should be initiated at lower doses than those recommended in younger individuals or in patients without cardiac disease (see **WARNINGS; PRECAUTIONS, Geriatric Use;** and **DOSAGE AND ADMINISTRATION**). If cardiac symptoms develop or worsen, the levothyroxine dose should be reduced or withheld for one week and then cautiously restarted at a lower dose. Overtreatment with levothyroxine sodium may have adverse cardiovascular effects such as an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias. Patients with coronary artery disease who are receiving levothyroxine therapy should be monitored closely during surgical procedures, since the possibility of precipitating cardiac arrhythmias may be greater in those treated with levothyroxine. Concomitant administration of levothyroxine and sympathomimetic agents to patients with coronary

artery disease may precipitate coronary insufficiency.

Patients with nontoxic diffuse goiter or nodular thyroid disease- Exercise caution when administering levothyroxine to patients with nontoxic diffuse goiter or nodular thyroid disease in order to prevent precipitation of thyrotoxicosis (see **WARNINGS**). If the serum TSH is already suppressed, levothyroxine sodium should not be administered (see **Contraindications**).

Associated endocrine disorders

<u>Hypothalamic/pituitary hormone deficiencies</u> - In patients with secondary or tertiary hypothyroidism, additional hypothalamic/pituitary hormone deficiencies should be considered, and, if diagnosed, treated (see **PRECAUTIONS, Autoimmune polyglandular syndrome** for adrenal insufficiency).

Autoimmune polyglandular syndrome - Occasionally, chronic autoimmune thyroiditis may occur in association with other autoimmune disorders such as adrenal insufficiency, pernicious anemia, and insulin-dependent diabetes mellitus. Patients with concomitant adrenal insufficiency should be treated with replacement glucocorticoids prior to initiation of treatment with levothyroxine sodium. Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. Patients with diabetes mellitus may require upward adjustments of their antidiabetic therapeutic regimens when treated with levothyroxine (see **PRECAUTIONS, Drug Interactions**).

Other associated medical conditions

Infants with congenital hypothyroidism appear to be at increased risk for other congenital anomalies, with cardiovascular anomalies (pulmonary stenosis, atrial septal defect, and ventricular septal defect,) being the most common association.

Information for Patients

Patients should be informed of the following information to aid in the safe and effective use of Levothyroxine Sodium Tablets, USP:

- 1. Notify your physician if you are allergic to any foods or medicines, are pregnant or intend to become pregnant, are breast-feeding or are taking any other medications, including prescription and over-the-counter preparations.
- 2. Notify your physician of any other medical conditions you may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems. Your dose of medications used to control these other conditions may need to be adjusted while you are taking Levothyroxine Sodium Tablets, USP. If you have diabetes, monitor your blood and/or urinary glucose levels as directed by your physician and immediately report any changes to your physician. If you are taking anticoagulants (blood thinners), your clotting status should be checked frequently.
- 3. Use Levothyroxine Sodium Tablets, USP only as prescribed by your physician. Do not discontinue or change the amount you take or how often you take it, unless directed to do so by your physician.
- 4. The levothyroxine in Levothyroxine Sodium Tablets, USP is intended to replace a hormone that is normally produced by your thyroid gland. Generally, replacement therapy is to be taken for life, except in cases of transient hypothyroidism, which is usually associated with an inflammation of the thyroid gland (thyroiditis).
- 5. Take Levothyroxine Sodium Tablets, USP in the morning on an empty stomach, at least one-half hour to one hour before eating any food.
- 6. It may take several weeks before you notice an improvement in your symptoms.
- 7. Notify your physician if you experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.
- 8. Notify your physician if you become pregnant while taking Levothyroxine Sodium Tablets, USP. It

is likely that your dose of Levothyroxine Sodium Tablets, USP will need to be increased while you are pregnant.

- 9. Notify your physician or dentist that you are taking Levothyroxine Sodium Tablets, USP prior to any surgery.
- 10. Partial hair loss may occur rarely during the first few months of Levothyroxine Sodium Tablets, USP therapy, but this is usually temporary.
- 11. Levothyroxine Sodium Tablets, USP should not be used as a primary or adjunctive therapy in a weight control program.
- 12. Keep Levothyroxine Sodium Tablets, USP out of the reach of children. Store Levothyroxine Sodium Tablets, USP away from heat, moisture, and light.
- 13. Agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine sodium tablets. Therefore, levothyroxine sodium tablets should not be administered within 4 hrs of these agents.

Laboratory Tests

<u>General</u>

The diagnosis of hypothyroidism is confirmed by measuring TSH levels using a sensitive assay (second generation assay sensitivity ≤ 0.1 mlU/L or third generation assay sensitivity ≤ 0.01 mlU/L) and measurement of free-T ₄.

The adequacy of therapy is determined by periodic assessment of appropriate laboratory tests and clinical evaluation. The choice of laboratory tests depends on various factors including the etiology of the underlying thyroid disease, the presence of concomitant medical conditions, including pregnancy, and the use of concomitant medications (see **PRECAUTIONS, Drug Interactions** and **Drug-Laboratory Test Interactions**). Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of Levothyroxine Sodium Tablets, USP may be evidence of inadequate absorption, poor compliance, drug interactions, or decreased T₄ potency of the drug product.

<u>Adults</u>

In adult patients with primary (thyroidal) hypothyroidism, serum TSH levels (using a sensitive assay) alone may be used to monitor therapy. The frequency of TSH monitoring during levothyroxine dose titration depends on the clinical situation but it is generally recommended at 6-8 week intervals until normalization. For patients who have recently initiated levothyroxine therapy and whose serum TSH has normalized or in patients who have had their dosage of levothyroxine changed, the serum TSH concentration should be measured after 8-12 weeks. When the optimum replacement dose has been attained, clinical (physical examination) and biochemical monitoring may be performed every 6-12 months, depending on the clinical situation, and whenever there is a change in the patient's status. It is recommended that a physical examination and a serum TSH measurement be performed at least annually in patients receiving Levothyroxine Sodium Tablets, USP. (see WARNINGS, PRECAUTIONS and DOSAGE AND ADMINISTRATION).

<u>Pediatrics</u>

In patients with congenital hypothyroidism, the adequacy of replacement therapy should be assessed by measuring both serum TSH (using a sensitive assay) and total- or free-T ₄. During the first three years of life, the serum total- or free-T ₄ should be maintained at all times in the upper half of the normal range. While the aim of therapy is to also normalize the serum TSH level, this is not always possible in a small percentage of patients, particularly in the first few months of therapy. TSH may not normalize due to a resetting of the pituitary-thyroid feedback threshold as a result of *in utero* hypothyroidism. Failure of the serum T ₄ to increase into the upper half of the normal range within 2 weeks of initiation of Levothyroxine Sodium Tablets, USP therapy and/or of the serum TSH to decrease below 20 mU/L within 4 weeks should alert the physician to the possibility that the child is not receiving adequate therapy. Careful inquiry should then be made regarding compliance, dose of medication administered,

and method of administration prior to raising the dose of Levothyroxine Sodium Tablets, USP.

The recommended frequency of monitoring of TSH and total or free T₄ in children is as follows: at 2 and 4 weeks after the initiation of treatment; every 1-2 months during the first year of life; every 2-3 months between 1 and 3 years of age; and every 3 to 12 months thereafter until growth is completed. More frequent intervals of monitoring may be necessary if poor compliance is suspected or abnormal values are obtained. It is recommended that TSH and T₄ levels, and a physical examination, if indicated, be performed 2 weeks after any change in Levothyroxine Sodium Tablets, USP dosage. Routine clinical examination, including assessment of mental and physical growth and development, and bone maturation should be performed at regular intervals (see **PRECAUTIONS, Pediatric Use** and **DOSAGE AND ADMINISTRATION**).

Secondary (pituitary) and tertiary (hypothalamic) hypothyroidism

Adequacy of therapy should be assessed by measuring serum free-T₄ levels, which should be maintained in the upper half of the normal range in these patients.

Drug Interactions

Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Tablets, USP. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and action of other drugs. A listing of drug-thyroidal axis interactions is contained in Table 2.

The list of drug-thyroidal axis interactions in Table 2 may not be comprehensive due to the introduction of new drugs that interact with the thyroidal axis or the discovery of previously unknown interactions. The prescriber should be aware of this fact and should consult appropriate reference sources (e.g., package inserts of newly approved drugs, medical literature) for additional information if a drug-drug interaction with levothyroxine is suspected.

Drug or Drug Class	Effect				
Drugs that may	Drugs that may reduce TSH secretion - the reduction is not sustained;				
tł	nerefore, hypothyroidism does not occur				
Dopamine/Dopamine Agonists Glucocorticoids Octreotide	Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: dopamine ($\geq 1 \text{ mcg/kg/min}$); Glucocorticoids (hydrocortisone $\geq 100 \text{ mg/day}$ or equivalent); Octreotide ($> 100 \text{ mcg/day}$).				
D	rugs that alter thyroid hormone secretion				
Drugs that may decrease thyroid hormone secretion, which may result in hypothyroidism					
Aminoglutethimide Amiodarone Iodide (including iodine-containing Radiographic contrast agents) Lithium Methimazole Propylthioracil (PTU)	Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine- induced hypothyroidism. Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated				

Table 2: Drug-Thyroidal Axis Interactions

Sulfonamides Tolbutamide	contrast agents. Long-term amino-glu-tethimide therapy may minimally decrease T $_4$ and T $_3$ levels and increase TSH,
	although all values remain within normal limits in most patients.
Drugs that may inc hyperthyroidism	rease thyroid hormone secretion, which may result in
Amiodarone Iodide (including iodine-containing Radiographic contrast agents)	Iodide and drugs that contain pharmacologic amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyper functioning thyroid adenoma). Hyperthyroidism may develop over several weeks and may persist for several months after therapy discontinuation. Amiodarone may induce hyperthyroidism by causing thyroiditis.
Drugs that may de	crease T_4 absorption, which may result in hypothyroidism
Antacids - Aluminum & Magnesium Hydroxides - Simethicone Bile Acid Sequestrants - Cholestyramine - Colestipol Calcium Carbonate Cation Exchange Resins - Kayexalate Ferrous Sulfate Orlistat Sucralfate	Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. Administer levothyroxine at least 4 hours apart from these agents. Patients treated concomitantly with orlistat and levothyroxine should be monitored for changes in thyroid function.
Drugs that may	alter T_4 and T_3 serum transport - but FT_4 concentration
remains no	rmal; and, therefore, the patient remains euthyroid
Drugs that may	Drugs that may decrease serum TBG concentration
increase serum TBG concentration	
Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen	Androgens / Anabolic Steroids
	ise protein-binding site displacement
Furosemide (> 80 mg IV) Heparin Hydantoins Non Steroidal Anti-	Administration of these agents with levothyroxine results in an initial transient increase in FT $_4$. Continued administration results in a decrease in serum T $_4$ and normal FT $_4$ and TSH concentrations and, therefore, patients are clinically

- Fenamates	followed by return of FT $_4$ to normal levels with sustained
- Phenylbutazone	therapeutic serum salicylate concentrations, although total-T
Salicylates (> 2	$_4$ levels may decrease by as much as 30%.
g/day)	

Drugs that may alter T_4 and T_3 metabolism				
Drugs that may increase hepatic metabolism, which may result in				
	hypothyroidis m			
Carbamazepine	Stimulation of hepatic microsomal drug-metabolizing enzyme			
Hydantoins	activity may cause increased hepatic degradation of			
Phenobarbital	levothyroxine, resulting in increased Ievothyroxine			
Rifampin	requirements. Phenytoin and carbamazepine reduce serum			
	protein binding of levothyroxine, and total- and free-T ₄ may			
	be reduced by 20% to 40%, but most patients have normal			
	serum TSH levels and are clinically euthyroid.			
Drugs	s that may decrease $T_4 5'$ - deiodinase activity			
Amiodarone	Administration of these enzyme inhibitors decrease the			
Beta-adrenergic	peripheral conversion of T $_4$ to T $_3$, leading to decreased T $_3$			
antagonists	levels. However, serum T ₄ levels are usually normal but			
- (e.g., Propranolol	may occasionally be slightly increased. In patients treated			
> 160 mg/day)	with large doses of propranolol ($> 160 \text{ mg/day}$), T ₃ and T ₄			
Glucocorticoids	levels change slightly, TSH levels remain normal, and			
-(e.g.,	patients are clinically euthyroid. It should be noted that			
Dexame thas one ≥ 4	actions of particular beta-adrenergic antagonists may be			
mg/day)	impaired when the hypothyroid patient is converted to the			
Propylthiouracil	euthyroid state. Short-term administration of large doses of			
(PTU)	glucocorticoids may decrease serum T $_3$ concentrations by			
	30% with minimal change in serum T $_4$ levels. However,			
	long-term glucocorticoid therapy may result in slightly			
	decreased T $_3$ and T $_4$ levels due to decreased TBG			
	production (see above).			
	Miscellaneous			
Anticoagulants	Thyroid hormones appear to increase the catabolism of			
(oral)	vitamin K-dependent clotting factors, thereby increasing the			
- Coumarin	anticoagulant activity of oral anticoagulants. Concomitant use			
Derivatives	of these agents impairs the compensatory increases in			
- Indandione	clotting factor synthesis. Prothrombin time should be			
Derivatives	carefully monitored in patients taking levothyroxine and oral			
	anticoagulants and the dose of anticoagulant therapy adjusted			
	accordingly.			
Antidepressants	Concurrent use of tri/tetracyclic antidepressants and			
- Tricyclics (e.g.,	levothyroxine may increase the therapeutic and toxic effects			
Amitriptyline)	of both drugs, possibly due to increased receptor sensitivity			
- Tetracyclics (e.g.,	to catecholamines.Toxic effects may include increased risk			
Maprotiline)	of cardiac arrhythmias and CNS stimulation; onset of action			
- Selective	of tricyclics may be accelerated. Administration of sertraline			
Serotonin Reuptake	in patients stabilized on levothyroxine may result in increased			
Inhibitors (SSRIs;	levothyroxine requirements.			
e.g., Sertraline)				
	Addition of lowoth moving to articlishatic or insulin thereas			
Antidiabetic Agents	Addition of levothyroxine to antidiabetic or insulin therapy			
- Biguanides Maglitipidas	may result in increased antidiabetic agent or insulin			
- Meglitinides	requirements. Careful monitoring of diabetic control is			
- Sulfonylureas	recommended, especially when thyroid therapy is started,			

- Thiazolidediones - Insulin	changed, or discontinued.
Cardiac Glycosides	Serum digitalis glycoside levels may be reduced in hyperthyroidism or when the hypothyroid patient is converted to the euthyroid state. Therapeutic effect of digitalis glycosides may be reduced.
Cytokines - Interferon-α - Interleukin-2	Therapy with interferon- α has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both. Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment. Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients. Interferon- β and - γ have not been reported to cause thyroid dysfunction.
Growth Hormones - Somatrem - Somatropin	Excessive use of thyroid hormones with growth hormones may accelerate epiphyseal closure. However, untreated hypothyroidism may interfere with growth response to growth hormone.
Ketamine	Concurrent use may produce marked hypertension and tachycardia; cautious administration to patients receiving thyroid hormone therapy is recommended.
Methylxanthine Bronchodilators - (e.g., Theophylline) Radiographic	Decreased theophylline clearance may occur in hypothyroid patients; clearance returns to normal when the euthyroid state is achieved. Thyroid hormones may reduce the uptake of ¹²³ I, ¹³¹ I, and
Agents Sympathomimetics	^{99m} Tc. Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
Chloral Hydrate Diazepam Ethionamide Lovastatin Metoclopramide 6-Mercaptopurine Nitroprusside Para-aminosalicylate sodium Perphenazine Resorcinol (excessive topical use) Thiazide Diuretics	These agents have been associated with thyroid hormone and/or TSH level alterations by various mechanisms.

<u>Oral anticoagulants</u> - Levothyroxine increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the Levothyroxine Sodium Tablets, USP dose is increased. Prothrombin time should be closely monitored to permit appropriate and timely dosage adjustments (see **Table 2**).

<u>Digitalis glycosides</u> - The therapeutic effects of digitalis glycosides may be reduced by levothyroxine. Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides (see **Table 2**).

Drug-Food Interactions

Consumption of certain foods may affect levothyroxine absorption thereby necessitating adjustments in dosing. Soybean flour (infant formula), cotton seed meal, walnuts, and dietary fiber may bind and decrease the absorption of levothyroxine sodium from the GI tract.

Drug-Laboratory Test Interactions

Changes in TBG concentration must be considered when interpreting T₄ and T₃ values, which necessitates measurement and evaluation of unbound (free) hormone and/or determination of the free T₄ index (FT₄I). Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Decreases in TBG concentrations are observed in nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, and after androgen or corticosteroid therapy (see also **Table 2**). Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of levothyroxine. The synthetic T₄ in Levothyroxine Sodium Tablets, USP is identical to that produced naturally by the human thyroid gland. Although there has been a reported association between prolonged thyroid hormone therapy and breast cancer, this has not been confirmed. Patients receiving Levothyroxine Sodium Tablets, USP for appropriate clinical indications should be titrated to the lowest effective replacement dose.

Pregnancy - Category A

Studies in women taking levothyroxine sodium during pregnancy have not shown an increased risk of congenital abnormalities. Therefore, the possibility of fetal harm appears remote. Levothyroxine Sodium Tablets, USP should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.

Hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, pre-eclampsia, stillbirth and premature delivery. Maternal hypothyroidism may have an adverse effect on fetal and childhood growth and development. During pregnancy, serum T ₄ levels may decrease and serum TSH levels increase to values outside the normal range. Since elevations in serum TSH may occur as early as 4 weeks gestation, pregnant women taking Levothyroxine Sodium Tablets, USP should have their TSH measured during each trimester. An elevated serum TSH level should be corrected by an increase in the dose of Levothyroxine Sodium Tablets, USP. Since postpartum TSH levels are similar to preconception values, the Levothyroxine Sodium Tablets, USP dosage should return to the pre-pregnancy dose immediately after delivery. A serum TSH level should be obtained 6-8 weeks postpartum.

Thyroid hormones cross the placental barrier to some extent as evidenced by levels in cord blood of athyroceotic fetuses being approximately one third maternal levels. Transfer of thyroid hormone from the mother to the fetus, however, may not be adequate to prevent *in utero*, hypothyroidism.

Nursing Mothers

Although thyroid hormones are excreted only minimally in human milk, caution should be exercised when Levothyroxine Sodium Tablets, USP is administered to a nursing woman. However, adequate replacement doses of levothyroxine are generally needed to maintain normal lactation.

Pediatric Use

<u>General</u>

The goal of treatment in pediatric patients with hypothyroidism is to achieve and maintain normal intellectual and physical growth and development.

The initial dose of levothyroxine varies with age and body weight (see **DOSAGE AND ADMINISTRATION**, **Table 3**). Dosing adjustments are based on an assessment of the individual patient's clinical and laboratory parameters (see **PRECAUTIONS**, **Laboratory Tests**).

In children in whom a diagnosis of permanent hypothyroidism has not been established, it is recommended that levothyroxine administration be discontinued for a 30-day trial period, but only after the child is at least 3 years of age. Serum T₄ and TSH levels should then be obtained. If the T₄ is low and the TSH high, the diagnosis of permanent hypothyroidism is established, and levothyroxine therapy should be reinstituted. If the T₄ and TSH levels are normal, euthyroidism may be assumed and, therefore, the hypothyroidism can be considered to have been transient. In this instance, however, the physician should carefully monitor the child and repeat the thyroid function tests if any signs or symptoms of hypothyroidism develop. In this setting, the clinician should have a high index of suspicion of relapse. If the results of the levothyroxine withdrawal test are inconclusive, careful follow-up and subsequent testing will be necessary.

Since some more severely affected children may become clinically hypothyroid when treatment is discontinued for 30 days, an alternate approach is to reduce the replacement dose of levothyroxine by half during the 30-day trial period. If, after 30 days, the serum TSH is elevated above 20 mU/L, the diagnosis of permanent hypothyroidism is confirmed, and full replacement therapy should be resumed. However, if the serum TSH has not risen to greater than 20 mU/L, levothyroxine treatment should be discontinued for another 30-day trial period followed by repeat serum T ₄ and TSH.

The presence of concomitant medical conditions should be considered in certain clinical circumstances and, if present, appropriately treated (see **PRECAUTIONS**).

<u>Congenital Hypothyroidism</u> (see **PRECAUTIONS, Laboratory Tests** and **DOSAGE AND ADMINISTRATION**)

Rapid restoration of normal serum T₄ concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, Levothyroxine Sodium Tablets, USP therapy should be initiated immediately upon diagnosis and is generally continued for life.

During the first 2 weeks of Levothyroxine Sodium Tablets, USP therapy, infants should be closely monitored for cardiac overload, arrhythmias, and aspiration from avid suckling.

The patient should be monitored closely to avoid undertreatment or overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment has been associated with craniosynostosis in infants, and may adversely affect the tempo of brain maturation and accelerate the bone age with resultant premature closure of the epiphyses and compromised adult stature.

Acquired Hypothyroidism in Pediatric Patients

The patient should be monitored closely to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.

Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height.

Geriatric Use

Because of the increased prevalence of cardiovascular disease among the elderly, levothyroxine therapy should not be initiated at the full replacement dose (see **WARNINGS, PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**).

ADVERSE REACTIONS

Adverse reactions associated with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage (see **PRECAUTIONS** and **OVERDOSAGE**). They include the following:

General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating;

Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia;

Musculoskeletal: tremors, muscle weakness;

Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest;

Respiratory: dyspnea;

Gastrointestinal: diarrhea, vomiting, abdominal cramps and elevation in liver function tests;

Dermatologic: hair loss; flushing;

Endocrine: decreased bone mineral density;

Reproductive: menstrual irregularities, impaired fertility.

Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised height.

Seizures have been reported rarely with the institution of levothyroxine therapy.

Inadequate levothyroxine dosage will produce or fail to ameliorate the signs and symptoms of hypothyroidism.

Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various Gl symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.

OVERDOSAGE

The signs and symptoms of overdosage are those of hyperthyroidism (see **PRECAUTIONS** and **ADVERSE REACTIONS**). In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures have occurred in a child ingesting 18 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.

Treatment of Overdosage

Levothyroxine sodium should be reduced in dose or temporarily discontinued if signs or symptoms of overdosage occur.

Acute Massive Overdosage - This may be a life-threatening emergency, therefore, symptomatic and supportive therapy should be instituted immediately. If not contraindicated (e.g., by seizures, coma, or loss of the gag reflex), the stomach should be emptied by emesis or gastric lavage to decrease gastrointestinal absorption. Activated charcoal or cholestyramine may also be used to decrease absorption. Central and peripheral increased sympathetic activity may be treated by administering β -receptor antagonists, e.g., propranolol, provided there are no medical contraindications to their use.

Provide respiratory support as needed; control congestive heart failure and arrhythmia; control fever, hypoglycemia, and fluid loss as necessary. Large doses of antithyroid drugs (e.g., methimazole or propylthiouracil) followed in one to two hours by large doses of iodine may be given to inhibit synthesis and release of thyroid hormones. Glucocorticoids may be given to inhibit the conversion of T ₄ to T ₃. Plasmapheresis, charcoal hemoperfusion and exchange transfusion have been reserved for cases in which continued clinical deterioration occurs despite conventional therapy. Because T ₄ is highly protein bound, very little drug will be removed by dialysis.

DOSAGE AND ADMINISTRATION

General Principles:

The goal of replacement therapy is to achieve and maintain a clinical and biochemical euthyroid state. The goal of suppressive therapy is to inhibit growth and/or function of abnormal thyroid tissue. The dose of Levothyroxine Sodium Tablets, USP that is adequate to achieve these goals depends on a variety of factors including the patient's age, body weight, cardiovascular status, concomitant medical conditions, including pregnancy, concomitant medications, and the specific nature of the condition being treated (see **WARNINGS** and **PRECAUTIONS**). Hence, the following recommendations serve only as dosing guidelines. Dosing must be individualized and adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters (see **PRECAUTIONS, Laboratory Tests**).

Levothyroxine Sodium Tablets, USP should be taken in the morning on an empty stomach, at least onehalf hour to one hour before any food is eaten. Levothyroxine Sodium Tablets, USP should be taken at least 4 hours apart from drugs that are known to interfere with its absorption (see **PRECAUTIONS**, **Drug Interactions**).

Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of levothyroxine sodium may not be attained for 4-6 weeks.

Caution should be exercised when administering Levothyroxine Sodium Tablets, USP to patients with underlying cardiovascular disease, to the elderly, and to those with concomitant adrenal insufficiency (see **PRECAUTIONS**).

Specific Patient Populations:

Hypothyroidism in Adults and in Children in Whom Growth and Puberty are Complete (see **WARNINGS** and **PRECAUTIONS**, Laboratory Tests).

Therapy may begin at full replacement doses in otherwise healthy individuals less than 50 years old and in those older than 50 years who have been recently treated for hyperthyroidism or who have been hypothyroid for only a short time (such as a few months). The average full replacement dose of levothyroxine sodium is approximately 1.7 mcg/kg/day (e.g., **100-125 mcg/day** for a 70 kg adult). Older patients may require less than 1 mcg/kg/day. Levothyroxine sodium doses greater than 200 mcg/day are seldom required. An inadequate response to daily doses \geq 300 mcg/day is rare and may indicate poor compliance, malabsorption, and/or drug interactions.

For most patients older than 50 years or for patients under 50 years of age with underlying cardiac disease, an initial starting dose of **25-50 mcg/day** of levothyroxine sodium is recommended, with gradual increments in dose at 6-8 week intervals, as needed. The recommended starting dose of levothyroxine sodium in elderly patients with cardiac disease is **12.5-25 mcg/day**, with gradual dose increments at 4-6 week intervals. The levothyroxine sodium dose is generally adjusted in 12.5-25 mcg increments until the patient with primary hypothyroidism is clinically euthyroid and the serum TSH has normalized.

In patients with severe hypothyroidism, the recommended initial levothyroxine sodium dose is **12.5-25 mcg/day** with increases of 25 mcg/day every 2-4 weeks, accompanied by clinical and laboratory assessment, until the TSH level is normalized.

In patients with secondary (pituitary) or tertiary (hypothalamic) hypothyroidism, the levothyroxine sodium dose should be titrated until the patient is clinically euthyroid and the serum free-T $_4$ level is restored to the upper half of the normal range.

<u>Pediatric Dosage - Congenital or Acquired Hypothyroidism</u> (see **PRECAUTIONS, Laboratory Tests**)

General Principles

In general, levothyroxine therapy should be instituted at full replacement doses as soon as possible. Delays in diagnosis and institution of therapy may have deleterious effects on the child's intellectual and physical growth and development.

Undertreatment and overtreatment should be avoided (see **PRECAUTIONS, Pediatric Use**).

Levothyroxine Sodium Tablets, USP may be administered to infants and children who cannot swallow intact tablets by crushing the tablet and suspending the freshly crushed tablet in a small amount (5-10 mL or 1-2 teaspoons) of water. This suspension can be administered by spoon or dropper. **DO NOT STORE THE SUSPENSION.** Foods that decrease absorption of levothyroxine, such as soybean infant formula, should not be used for administering levothyroxine sodium tablets. (see **PRECAUTIONS, Drug-Food Interactions**).

Newborns

The recommended starting dose of levothyroxine sodium in newborn infants is **10-15 mcg/kg/day**. A lower starting dose (e.g., 25 mcg/day) should be considered in infants at risk for cardiac failure, and the dose should be increased in 4-6 weeks as needed based on clinical and laboratory response to treatment. In infants with very low (< 5 mcg/dL) or undetectable serum T ₄ concentrations, the recommended initial starting dose is **50 mcg/day** of levothyroxine sodium.

Infants and Children

Levothyroxine therapy is usually initiated at full replacement doses, with the recommended dose per body weight decreasing with age (see **TABLE 3**). However, in children with chronic or severe hypothyroidism, an initial dose of **25 mcg/day** of levothyroxine sodium is recommended with increments of 25 mcg every 2-4 weeks until the desired effect is achieved.

Hyperactivity in an older child can be minimized if the starting dose is one-fourth of the recommended full replacement dose, and the dose is then increased on a weekly basis by an amount equal to one-fourth the full-recommended replacement dose until the full recommended replacement dose is reached.

AGE	Daily Dose Per Kg Body Weight ^a		
0-3 months	10-15 mcg/kg/day		
3-6 months	8-10 mcg/kg/day		
6-12 months	6-8 mcg/kg/day		
1-5 years	5-6 mcg/kg/day		
6-12 years	4-5 mcg/kg/day		
>12 years but growth and puberty incomplete	2-3 mcg/kg/day		
Growth and puberty complete 1.7 mcg/kg/day			
a. The dose should be adjusted based on clinical respon	se and laboratory parameters (see		
PRECAUTIONS, Laboratory Tests and Pediatric Us	e).		

Pregnancy- Pregnancy may increase levothyroxine requirements (see **PREGNANCY**).

Subclinical Hypothyroidism- If this condition is treated, a lower levothyroxine sodium dose (e.g., **1 mcg/kg/day**) than that used for full replacement may be adequate to normalize the serum TSH level.

Patients who are not treated should be monitored yearly for changes in clinical status and thyroid laboratory parameters.

TSH Suppression in Well-differentiated Thyroid Cancer and Thyroid Nodules- The target level for TSH suppression in these conditions has not been established with controlled studies. In addition, the efficacy of TSH suppression for benign nodular disease is controversial. Therefore, the dose of Levothyroxine Sodium Tablets, USP used for TSH suppression should be individualized based on the specific disease and the patient being treated.

In the treatment of well differentiated (papillary and follicular) thyroid cancer, levothyroxine is used as an adjunct to surgery and radioiodine therapy. Generally, TSH is suppressed to <0.1 mU/L, and this usually requires a levothyroxine sodium dose of **greater than 2 mcg/kg/day**. However, in patients with high-risk tumors, the target level for TSH suppression may be <0.01 mU/L.

In the treatment of benign nodules and nontoxic multinodular goiter, TSH is generally suppressed to a higher target (e.g., 0.1-0.5 mU/L for nodules and 0.5-1.0 mU/L for multinodular goiter) than that used for the treatment of thyroid cancer. Levothyroxine sodium is contraindicated if the serum TSH is already suppressed due to the risk of precipitating overt thyrotoxicosis (see **CONTRAINDICATIONS, WARNINGS** and **PRECAUTIONS**).

Myxedema Coma - Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Therefore, oral thyroid hormone drug products are not recommended to treat this condition. Thyroid hormone products formulated for intravenous administration should be administered.

HOW SUPPLIED

Strength (mcg)	Color	NDC# for bottles of 100	NDC# for bottles of 1000
25	Peach	NDC 0527-1341-01	NDC 0527-1341 -10
50	White	NDC 0527-1342-01	NDC 0527-1342 -10
75	Purple	NDC 0527-1343-01	NDC 0527-1343 -10
88	Olive	NDC 0527-1344-01	NDC 0527-1344 -10
100	Yellow	NDC 0527-1345-01	NDC 0527-1345 -10
112	Rose	NDC 0527-1346-01	NDC 0527-1346 -10
125	Tan	NDC 0527-1347-01	NDC 0527-1347 -10
137	Blue	NDC 0527-1638-01	NDC 0527-1638 -10
150	Lt. Blue	NDC 0527-1349-01	NDC 0527-1349 -10
175	Lilac	NDC 0527-1350-01	NDC 0527-1350 -10
200	Pink	NDC 0527-1351-01	NDC 0527-1351 -10
300	Green	NDC 0527-1352-01	NDC 0527-1352 -10

Levothyroxine Sodium Tablets, USP are round, color coded, partial bisected tablets debossed with JSP and ID Number:

STORAGE CONDITIONS

20°C to 25°C (68°F to 77°F) with excursions between 15°C to 30°C (59°F to 86°F)

Rx only

Manufactured for: **Lannett Company, Inc.** Philadelphia, PA 19136

Manufactured by:

Jerome Stevens Pharmaceuticals, Inc.

Bohemia, NY 11716

Rev. 10/07


MG #18326

Principal Display Panel

Levothyroxine Sodium Tablets, USP 50mcg (0.050mg)

30 Tablets

NDC 10544-229-30




Principal Display Panel

Levothyroxine Sodium Tablets, USP 75mcg (0.075mg)

30 Tablets

NDC 10544-228-30



Principal Display Panel

Levothyroxine Sodium Tablets, USP 100mcg (0.1mg)

30 Tablets

NDC 10544-260-30

NDC: 10544-260-30 LCN# 000 MFG: 0527-1345-10 Rev. 2 Levothyroxine Sodium Tablets, USP 100mcg (0.1mg) 30 Tablets	Inc	Pharmacal. Inc., 31 P0000000+0000	Levothyroxine Sodium Tablets, USP 100mcg (0.1mg) 30 Tablets NDC: 10544-260-30 MFG: 0527-1345-10 Lot #: BP00000000 Exp.Date: 00/00/0000 Levothyroxine Sodium Tablets, USP 100mcg (0.1mg) 30 Tablets NDC: 10544-260-30 MFG: 0527-1345-10 Lot #: BP00000000 Exp.Date: 00/00/0000	PEEL HERE
SU Fablets Rx Only Dosage: See package insert Store at controlled room temperature 20°-25°C (68°-77°F); Excursions permitted to 15°-30°C (59°-86°F) Store in a tight, light-resistant container (See USP). Keep out of the reach of children	Mfg: Lannett Company, I	Packaged By: Blenheim North Blenheim, NY 121 Lot #. BP0000000 Exp.Date: 00/00/0000 Exp.Date: 00/00/0000	Levothyroxine Sodium Tablets, USP 100mcg (0.1mg) 30 Tablets NDC: 10544-260-30 MFG: 0527-1345-10 Lot #: BP00000000 Exp.Date: 00/00/0000 Levothyroxine Sodium Tablets, USP 100mcg (0.1mg) 30 Tablets NDC: 10544-260-30 MFG: 0527-1345-10 Lot #: BP00000000 Exp.Date: 00/00/0000	PEEL HERE

Principal Display Panel

Levothyroxine Sodium Tablets, USP 125mcg (0.125mg)

30 Tablets

NDC 10544-262-30



Principal Display Panel

Levothyroxine Sodium Tablets, USP 137mcg (0.137mg)

30 Tablets

NDC 10544-264-30

NDC: 10544-264-30 LCN# 000 MFG: 0527-1638-10 Rev 1 Levothyroxine Sodium Tablets, USP 137mcg (0.137mg) 30 Tablets Rx Only Dosage: See package insert Store at controlled room temperature 20°-25°C (68°-77°F); Excursions permitted to 15°-30°C (59°-86°F) Store in a tight, light-resistant container (See USP). Keep out of the reach of children.		Mg: Lannett Company, Inc. Packaged By: Blenheim Pharmacal. Inc., North Blenheim, NY 12131 Lot #. BP00000000 Exp.Date: 00/00/0000 Exp.Date: 00/00/0000 1054426430+BP00000000+0000	Levothyroxine Sodium Tablets, USP 137mcg (0.137mg) 30 Tablets NDC: 10544-264-30 MFG: 0527-1638-10 Lot #: BP00000000 Exp.Date: 00/00/0000 Levothyroxine Sodium Tablets, USP 137mcg (0.137mg) 30 Tablets NDC: 10544-264-30 MFG: 0527-1638-10 Lot #: BP00000000 Exp.Date: 00/00/0000 Levothyroxine Sodium Tablets, USP 137mcg (0.137mg) 30 Tablets NDC: 10544-264-30 MFG: 0527-1638-10 Lot #: BP00000000 Exp.Date: 00/00/0000 Levothyroxine Sodium Tablets, USP 137mcg (0.137mg) 30 Tablets NDC: 10544-264-30 MFG: 0527-1638-10 Lot #: BP00000000 Exp.Date: 00/00/0000 Levothyroxine Sodium Tablets, USP 137mcg (0.137mg) 30 Tablets NDC: 10544-264-30 MFG: 0527-1638-10 Lot #: BP00000000 Exp.Date: 00/00/0000	PEEL HERE PEEL HERE
---	--	--	---	---------------------

Principal Display Panel

Levothyroxine Sodium Tablets, USP 150mcg (0.150mg)

30 Tablets

NDC 10544-266-30

NDC: 10544-266-30 LCN# 000 MFG: 0527-1349-10 Rev 1 Levothyroxine Sodium Tablets, USP 150mcg (0.15mg) 30 Tablets	. Inc. n Pharmacal, Inc., 131 3P0000000+00000	Levothyroxine Sodium Tablets, USP 150mcg (0.15mg) 30 Tablets NDC: 10544-266-30 MFG: 0527-1349-10 Lot #: BP00000000 Exp.Date: 00/00/0000 Levothyroxine Sodium Tablets, USP 150mcg (0.15mg) 30 Tablets NDC: 10544-266-30 MFG: 0527-1349-10 Lot #: BP00000000 Exp.Date: 00/00/0000
Rx Only Dosage: See package insert Store at controlled room temperature 20°-25°C (68°-77°F); Excursions permitted to 15°-30°C (59°-86°F) Store in a tight, light-resistant container (See USP). Keep out of the reach of children	Mfg. Lannett Company, Inc Packaged By: Blenheim Ph North Blenheim, NY 12131 Lot #: BP0000000 Exp.Date: 00/00/0000 Exp.Date: 00/00/0000 1054426630+BP0	Levothyroxine Sodium Tablets, USP 150mcg (0.15mg) 30 Tablets NDC: 10544-266-30 MFG: 0527-1349-10 Lot #: BP00000000 Exp.Date: 00/00/0000 Levothyroxine Sodium Tablets, USP 150mcg (0.15mg) 30 Tablets NDC: 10544-266-30 MFG: 0527-1349-10 Lot #: BP00000000 Exp.Date: 00/00/0000

Principal Display Panel

Levothyroxine Sodium Tablets, USP 25mcg (0.025mg)


30 Tablets

NDC 10544-247-30

NDC: 10544-247-30 LCN# 000 MFG: 0527-1341-10 Rev 2 Levothyroxine Sodium Tablets, USP 25mcg (0.025mg) 30 Tablets Rx Only Dosage: See package insert Store at controlled room temperature 20°-25°C (68°-77°F); Excursions permitted to 15°-30°C (59°-86°F) Store in a tight, light-resistant container (See USP). Keep out of the reach of children	Mig. Lannett Company, Inc. Frackaged By: Bienheim, NY 12131 NDC: 10247-547-30 Packaged By: Bienheim, NY 12131 NDC: 10247-547-30 Pottom Source Packaged By: Bienheim, NY 12131 Inc. NDC: 10247-547-30 Pottom Source Packaged By: Bienheim, NY 12131 Inc. Icot #: Bbo0000000 Fxp Date: 00/000000 Fxp Date: 00/000000 Fxp Date: 00/00000 Fxp Date: 00/000000 Fxp Date: 00/00000 Fxp Date: 00/00000 Fxp Date: 00/00000 Fxp Date: 00/00000 Fxp Date: 00/00000 Fxp Date: 00/000000 Fxp Date: 00/00000 Fxp Date: 00/000000 Fxp Date: 00/00000 Fxp Date: 00/00000 Fxp Date: 00/00000	30 Tablets MFG: 0527-1341-10 Exp.Date: 00/00/0000 m Tablets, USP 30 Tablets MFG: 0527-1341-10 Exp.Date: 00/00/0000 m Tablets, USP 30 Tablets MFG: 0527-1341-10 Exp.Date: 00/00/0000
---	--	---

DESCRIPTION

Levothyroxine Sodium Tablets, USP contain synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T ₄) sodium]. Synthetic T ₄ is identical to that produced in the human thyroid gland. Levothyroxine (T ₄) sodium has an empirical formula of C ₁₅H ₁₀I ₄N NaO ₄ • H ₂O, molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:



Inactive Ingredients

Colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, corn starch, acacia and sodium starch glycolate. The following are the coloring additives per tablet strength:

Strength	
(mcg)	Color Additive(s)
25	FD&C Yellow No. 6 Aluminum Lake
50	None
75	FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake
88	D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
100	D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake
112	D&C Red No. 27 Aluminum Lake
125	FD&C Yellow No. 6 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
137	FD&C Blue No. 1 Aluminum Lake
150	FD&C Blue No. 2 Aluminum Lake
175	FD&C Blue No. 1 Aluminum Lake, D&C Red No. 27 Aluminum Lake
200	FD&C Red No. 40 Aluminum Lake
300	D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake

Principal Display Panel

Levothyroxine Sodium Tablets, USP 88mcg (0.088mg)

30 Tablets

NDC 10544-258-30



Principal Display Panel

Levothyroxine Sodium Tablets, USP 112mcg (0.112mg)

30 Tablets

NDC 10544-261-30



LEVOTHYROXINE SODIUM

levothyroxine sodium tablet

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:10544-247(NDC:0527-1341)
Route of Administration	ORAL		

	Ingredient Name		Basis of Stren	gth Strengt
LEVOTHYROXINE UNII:Q51BO43MG4)	SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE -	LEVOTHYROXINE SODI ANHYDROUS	UM .025 mg
Inactive Ingred				
		redient Name		Strength
	(UNII: ETJ7Z6XBU4)			
L ACTOSE (UNII: J2H				
	RATE (UNII: 70097M6I30)			
	CRYSTALLINE (UNII: OP1R	32D61U)		
STARCH, CORN (UI				
ACACIA (UNII: 5C54				
	GLYCOLATE TYPE A POTAT	O (UNII: 5856J3G2A2)		
). 6 (UNII: H77VEI93A8) (UNII: LMI2606933)			
Product Charac				
Color	orange (Peach)	Score		2 pieces
Color Shape		Size		7mm
Color Shape Flavor	orange (Peach)		de	
Color Shape Flavor Contains	orange (Peach)	Size	de	7mm
Color Shape Flavor	orange (Peach)	Size	de	7mm
Color Shape Flavor Contains Packaging	orange (Peach) ROUND	Size	de Marketing Start Date	7mm
Color Shape Flavor Contains Packaging Item Code	orange (Peach) ROUND	Oescription	Marketing Start	7mm JSP;513 Marketing End
Color Shape Flavor Contains Cont	orange (Peach) ROUND BOUND BOU	Oescription	Marketing Start Date	7mm JSP;513 Marketing End
Color Shape Flavor Contains Packaging Item Code NDC:10544-247- 30 Marketing In	orange (Peach) ROUND ROUND and and a second	Description Page 0: Not a Combination	Marketing Start Date 11/15/2013	7mm JSP;513 Marketing End Date
Color Shape Flavor Contains Vackaging Item Code	orange (Peach) ROUND ROUND and and a second	Size Imprint Control Description rpe 0: Not a Combination or Monograph Citation	Marketing Start Date	7mm JSP;513 Marketing End

LEVOTHYROXINE SODIUM

levothyroxine sodium tablet

Product Information			
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:10544-229(NDC:0527-1342)
Route of Administration	ORAL		

	Active M	5						
	Ingre	edient Name			Basi	s of Stre	ngth	Strengt
LEVO THYRO XINE SO UNII:Q51BO43MG4)) DIUM (UNII:	9J765S329G) (LEVO1	THYRO XINE -		LEVOTHYRO ANHYDROUS		DIUM	.05 mg
Inactive Ingredie	nts							
		Ingredien	nt Name					Strength
SILICON DIO XIDE (UN	NII: ETJ7Z6XI	3U4)						
LACTOSE (UNII: J2B2A								
MAGNESIUM STEARA								
CELLULOSE, MICRO			J)					
STARCH, CORN (UNII:		()						
ACACIA (UNII: 5C5403)								
SODIUM STARCH GLY	YCOLATE T	YPE A POTATO (UNI	II: 5856J3G2A2))				
Product Characte	ristics							
Color	whit	e	Score				2 pieces	
Shape	ROU	JND	Size				7mm	
Flavor			Imprint Cod	e			JSP;514	
Flavor Contains			Imprint Cod	e			JSP;514	
			Imprint Cod	e			JSP;514	
Contains			Imprint Cod	e			JSP;514	
Contains Packaging		Package Descri		e	Marketin Dat	ng Start		keting End Date
Contains Packaging # Item Code 1 NDC:10544-229- 3	0 in 1 BOTTL roduct	Package Descri j E, PLASTIC; Type 0: N	ption			ng Start		-
Contains Packaging # Item Code 1 NDC:10544-229- 3			ption		Dat	ng Start		-
Contains Packaging # Item Code 1 NDC:10544-229- 3 P	Product	E, PLASTIC; Type 0: N	ption		Dat	ng Start		-
Contains Packaging # Item Code 1 NDC:10544-229- 3 P Marketing Info	product	E, PLASTIC; Type 0: N	ption Not a Combinati	ion	Dat	ıg Start te	Marl	Date
Contains Packaging # Item Code 1 NDC:10544-229- 3	product	E, PLASTIC; Type 0: N I tion Number or Mon	ption Not a Combinati	ion tion N	Dat	ıg Start te	Marl	-
Contains Packaging I Item Code I NDC:10544-229- 3 ONDC:10544-229- 3 NDC:10544-229- 3 NDC:10544-244-229- 3 NDC:10544-244-244-244-244-244-244-244-244-244-	product Drmation Applica	E, PLASTIC; Type 0: N I tion Number or Mon	ption Not a Combinati	ion tion N	Dat 0 2/13/20 12 Marketing Sta	ıg Start te	Marl	Date
Contains Packaging I Item Code NDC:10544-229- 3 ONDC:10544-229- 3 NDC:10544-229- 3 NDC:1054	product Drmation Applica	E, PLASTIC; Type 0: N I tion Number or Mon	ption Not a Combinati	ion tion N	Dat 0 2/13/20 12 Marketing Sta	ıg Start te	Marl	Date
Contains Packaging I Item Code I NDC:10544-229- 3 P Marketing Info Marketing Category NDA	Product Drmation Applica NDA021210	E, PLASTIC; Type 0: N l tion Number or Mon	ption Not a Combinati	ion tion N	Dat 0 2/13/20 12 Marketing Sta	ıg Start te	Marl	Date
Contains Packaging I Item Code I NDC:10544-229- 3 DO:10544-229- 3 NDA Marketing Category NDA LEVOTHYRO	Troduct Troduc	E, PLASTIC; Type 0: N l tion Number or Mon	ption Not a Combinati	ion tion N	Dat 0 2/13/20 12 Marketing Sta	ıg Start te	Marl	Date
Contains Packaging I Item Code I NDC:10544-229- 3 DO:10544-229- 3 NDA NDA LEVOTHYRO	Troduct Troduc	E, PLASTIC; Type 0: N l tion Number or Mon	ption Not a Combinati	ion tion N	Dat 0 2/13/20 12 Marketing Sta	ıg Start te	Marl	Date
Contains Packaging I Item Code NDC:10544-229- 3 Marketing Info Marketing Category NDA LEVOTHYRO2	Product Primation Applica NDA021210 XINE SO n tablet	E, PLASTIC; Type 0: N l tion Number or Mon	ption Not a Combinati	ion tion N	Dat 0 2/13/20 12 Marketing Sta	ıg Start te	Marl	Date
Contains Packaging I Item Code NDC:10544-229- 3 Marketing Info Marketing Category NDA LEVOTHYRO2	Product Primation Applica NDA021210 XINE SO n tablet	E, PLASTIC; Type 0: N l tion Number or Mon	ption Not a Combinati	ion tion N	Dat 0 2/13/20 12 Marketing Sta	ıg Start te	Marl	Date
Contains Packaging I Item Code I NDC:10544-229- 3 DO:10544-229- 3 NDA NDA LEVOTHYRO	Product Primation Applica NDA021210 XINE SO n tablet	E, PLASTIC; Type 0: N l tion Number or Mon	ption Not a Combination nograph Citat	ion tion N 02	Dat 0 2/13/20 12 Marketing Sta	ig Start te	Marketi	Date

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE -	LEVOTHYROXINE SODIUM	0.75 mg		

	ents					
	Ingredient Name					
SILICON DIOXIDE (UNII: ETJ7	Z6XBU4)				
L ACTOSE (UNII: J2B	2A4N98G))				
MAGNESIUM STEAH	RATE (UNI	I:70097M6I30)				
CELLULOSE, MICR	OCRYSTA	LLINE (UNII: OP1R321	D6 1U)			
STARCH, CORN (UN	III: 08232N	IY3SJ)				
ACACIA (UNII: 5C540)3N26O)					
SO DIUM STARCH G	LYCOLA	ГЕ ТҮРЕ А РОТАТО	(UNII: 5856J3G2A2)			
FD&C RED NO.40 (UNII: WZB9	9127XOA)				
D&C BLUE NO.2 (UNII: L06K	K8R7DQK)				
ALUMINUM O XIDE	(UNII: LMI2	2606933)				
Product Charac	teristics					
Color		purple	Score		2 pieces	
Shape		ROUND	Size		7mm	
Flavor			Imprint Code		JSP;515	
Contains						
Packaging						
# Item Code		Package Des	scription	Marketing Start Date	Marketing End Date	
NDC:10544-228-	30 in 1 BC Product	OTTLE, PLASTIC; Type	e 0: Not a Combination	12/20/2010		
30						
30						
30	format	ion				
Marketing In			Monograph Citation	Marketing Start Date	Marketing End Dat	

LEVOTHYROXINE SOD	IUM				
levothyroxine sodium tablet					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Co	de (Source)	NDC:10544-260(NI	DC:0527-1345)
Route of Administration	ORAL				
Active Ingredient/Active Moi	ety				
Ingred	ient Name		Basis	s of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J UNII:Q51BO43MG4)	765S329G) (LEVOTHYROXINE -		LEVOTHYRO ANHYDROUS	XINE SODIUM	.1 mg

Inactive Ingredi	ients					
		Ingredi	ient Name		Strength	
SILICON DIO XIDE (UNII: ETJ72	Z6 XBU4)				
LACTOSE (UNII: J2B	32A4N98G))				
MAGNESIUM STEAP	RATE (UNI	E: 70097M6I30)				
CELLULOSE, MICR	OCRYSTA	LLINE (UNII: OP1R32D6	6 1U)			
STARCH, CORN (UN	III: O8232N	Y3SJ)				
ACACIA (UNII: 5C540)3N26O)					
SODIUM STARCH G	LYCOLAT	ΓΕ ΤΥΡΕ Α ΡΟΤΑΤΟ (U	JNII: 5856J3G2A2)			
D&C YELLOW NO.	10 (UNII: 3	5SW5USQ3G)				
FD&C YELLOW NO	.6 (UNII: H	177VE193A8)				
ALUMINUM O XIDE	(UNII: LMI2	606933)				
Product Charac	teristics	vellow	Score		2 nieces	
Color		yello w	Score		2 pieces	
Shape		ROUND	Size		7mm	
Flavor			Imprint Code		JSP;516	
Contains						
Contains						
Contains						
Packaging		Package Desc	cription	Marketing Start Date	Marketing End Date	
Packaging	30 in 1 BC Product	Package Desc DTTLE, PLASTIC; Type (-			
Packaging # Item Code	Product): Not a Combination	Date		
P-ckaging Item Code 1 NDC:10544-260- 30 2 NDC:10544-260-	Product 90 in 1 BC)TTLE, PLASTIC; Type (): Not a Combination	Date 11/18/2013		
First starting Item Code 1 NDC:10544-260- 0 2 NDC:10544-260- 0	Product 90 in 1 BC Product	OTTLE, PLASTIC; Type (): Not a Combination	Date 11/18/2013		
P-ckaging Item Code 1 NDC:10544-260- 2 NDC:10544-260-	Product 90 in 1 BC Product	OTTLE, PLASTIC; Type (0: Not a Combination 0: Not a Combination	Date 11/18/2013	Date	

- /

LEVOTHYROXINE SODIUM					
levothyroxine sodium tablet					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Cod	le (Source)	NDC:10544-262(NDC:	0527-1347)
Route of Administration	ORAL				
Active Ingredient/Active Moi	ety				
Ingred	ient Name		Basi	s of Strength	Strength

	ients					
		Ingredient Na	me		Strength	
SILICON DIO XIDE	(UNII: E	TJ7Z6XBU4)				
LACTOSE (UNII: J2	B2A4N9	8G)				
MAGNESIUM STEA	RATE (UNII: 70097M6I30)				
CELLULOSE, MICI	ROCRYS	STALLINE (UNII: OP1R32D61U)				
STARCH, CORN (U	NII: O82	32NY3SJ)				
ACACIA (UNII: 5C54	03N260))				
SO DIUM STARCH	GLYCO	LATE TYPE A POTATO (UNII: 585	56J3G2A2)			
FD&C YELLOW NO	D.6 (UN	II: H77VEI93A8)				
FD&C RED NO.40	(UNII: W	ZB9127XOA)				
FD&C BLUE NO. 1	(UNII: H	3R47K3TBD)				
ALUMINUM O XIDE	(UNII: I	.MI26O6933)				
Product Chara	cterist	ics				
Color		brown (Tan)	Score		2 pieces	
Shape		ROUND	Size		7mm	
Flavor			Imprint Code	2	JSP;519	
Contains						
Packaging						
# Item Code		Package Description	n	Marketing Start Date	Marketing End Date	
1 NDC:10544-262-	30 in 1 Produ	l BOTTLE, PLASTIC; Type 0: Not a ct	Combination	11/18/2013		
30						
30						
Marketing I	nforn	nation				
		lation Application Number or Monogra	aph Citation	Marketing Start Date	Marketing End Date	

LEVOTHYROXINE SOD levothyroxine sodium tablet	IUM				
k voniyioxiik souluii tubkt					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Coo	de (Source)	NDC:10544-264(NDC	:0527-1638)
Route of Administration	ORAL				
Active Ingredient/Active Moi	ety				
Ingred	ient Name		Basi	s of Strength	Strength

LEVOTHYROXINE SODIUM ANHYDROUS

Inactive Ingred	ients					
		Ingr	edient Name			Strength
SILICON DIO XIDE	(UNII: ETJ7	Z6XBU4)				
LACTOSE (UNII: J21	B2A4N98G)				
MAGNESIUM STEA	RATE (UNI	I:70097M6I30)				
CELLULOSE, MICF	ROCRYSTA	LLINE (UNII: OP1R	32D61U)			
STARCH, CORN (UI	NII: 08232N	YY3SJ)				
ACACIA (UNII: 5C54	03N26O)					
SODIUM STARCH (GLYCOLA	ΓΕ ΤΥΡΕ Α ΡΟΤΑΤ	O (UNII: 5856J3G2A2)			
FD&C BLUE NO. 1	(UNII: H3R4	7K3TBD)				
ALUMINUM O XIDE	(UNII: LMI2	2606933)				
Product Charac	teristics					
Color		blue	Score		2 pieces	
Shape		ROUND	Size		7mm	
Flavor			Imprint Code		JSP;564	
Contains						
Dackaging						
Packaging				Marketing Start	Mai	ekating End
Packaging # Item Code		Package D	Description	Marketing Start Date	Mai	rketing End Date
# Item Code	30 in 1 BC	-	-	Date	Mai	rketing End Date
	30 in 1 BC Product	-	Description pe 0: Not a Combination		Mai	-
# Item Code		-	-	Date	Mai	-
 # Item Code 1 NDC:10544-264- 30 	Product	DTTLE, PLASTIC; Ty	-	Date	Mai	-
 <i>Item Code</i> ^{NDC:10544-264-} 30 Marketing In 	Product	DTTLE, PLASTIC; Ty	pe 0: Not a Combination	Date 11/18/20 13		Date
 # Item Code 1 NDC:10544-264- 30 Marketing In Marketing Catego 	Product Iformat Dry App	DTTLE, PLASTIC; Ty tion	-	Date 11/18/20 13 farketing Start Date		Date
 <i>Item Code</i> ^{NDC:10544-264-} 30 Marketing In 	Product	DTTLE, PLASTIC; Ty tion	pe 0: Not a Combination	Date 11/18/20 13		-

Product Information			
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:10544-266(NDC:0527-1349)
Route of Administration	ORAL		

Ingredient Name	Strength
EVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE -	1E ma
EVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE -	

hape ROUND Size 7mm lavor Imprint Code JSP;520 contains Imprint Code Marketing Start Item Code Package Description Marketing Start NDC:10544-266- 30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/18/2013 Inderketing Start Imprint Code Marketing End Date	UNII:Q51BO43MG4)			ANHYDROUS	gill cr.
Ingredient Name Strength LLCON DIO XIDE (UNIL: ETJ726 XBU4)					
ILICON DIO XIDE (UNIE ET1726 XBU4) ACTOSE (UNIE 12B2AAN98G) AGRESUM STEARATE (UNIE 70097M6180) EELLULOSE, MICRO CRYSTALLINE (UNIE 0PIR32D610) TARCH, CORN (UNIE 505403N260) CACIA (UNIE 505403N260) CODUM STARCH CL VCO LATE TYPE A POTATO (UNIE 5856J3G2A2) DB&C BLUE NO. 2 (UNIE L06K8R7DQK) LUMINUM O XIDE (UNIE LM2606933) Product Characteristics Solor blue (Light Blue) Score 2 pieces hape ROUND Size 700 2 pieces hape ROUND Size 700 2 pieces solor blue (Light Blue) Score 2 pieces hape 800ND Size 700 2 pieces solor 100 Marketing Size 700 1 pieces solor 100 1 pieces 700 1 pieces solor 100 1 pieces 700 1 pieces 700 1 pieces solor 100 1 pieces 700 1 p	Inactive Ingredi	ents			
ACTO SE (UNIE: J2B2A4N98G) AGORESIUM STEARATE (UNIE: 70097M6B0) FELULOSE, MICRO CKYSTALLINE (UNIE: 0018320610) TARCH, CORN (UNIE: 08321731) CACCIA (UNIE: 56303N26) ODIUM STARCH GLYCOLATE TYPE A POTATO (UNIE: 5856J3G2A2) DGL BLUE NO. 2 (UNIE: L06K8R7DQK) LUMINUM OXIDE (UNIE: H12606933) Product Charactersterstersterstersterstersterstersters		Ingredient	Name		Strength
tagnession stearate (UNII: 70097M6 B0) UNII: 70097M6 B0) UNII: 70097M6 B0) EELLULOSE, MICRO CRYSTALLINE (UNII: 0PIR32D6 IU) UNII: 70097M6 B0) UNII: 70097M6 B0) TARCH, CORN (UNII: 8232N735) UNII: 70097M6 B0) UNII: 70097M6 B0) CACIA (UNII: 5C5403N20) UNII: 70097M6 B0) UNII: 70097M6 B0) ODUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) UNII: 70097M6 B0) Dace BLUE NO. 2 (UNII: LO6K8R7DQK) UNII: 70097M6 B0) UNII: 70097M6 B0) Stage MICRO Characterize Score 2 pieces Solor Bule (Light Blue) Score 2 pieces Navor Bule (Light Blue) Size 7mm Iavor Bolue (Light Blue) Size 7mm Iavor Imprint Cote J89520 J89520 Sontains J10001 J10001 J997000000 NDC:10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination J10001 Marketing Start Date Marketing Category <t< td=""><td>SILICON DIO XIDE (</td><td>UNII: ETJ7Z6XBU4)</td><td></td><td></td><td></td></t<>	SILICON DIO XIDE (UNII: ETJ7Z6XBU4)			
ELLULOSE, MICRO CRYSTALLINE (UNII: OPIR32D6 IU) Image: State of the state of	LACTOSE (UNII: J2B	2A4N98G)			
TARCH, CORN (UNIE: 08232NY3SJ)	MAGNESIUM STEAF	RATE (UNII: 70097M6I30)			
CACIA (UNII: 5C5403N26O) Image: Comparison of the state of the	CELLULOSE, MICRO	OCRYSTALLINE (UNII: OP1R32D61U)			
ODIUM STARCH GLVCOLATE TYPE A POTATO (UNIE 5856/362A2) Image: Starch GLVCOLATE TYPE A POTATO (UNIE 5856/362A2) D&C BLUE NO. 2 (UNIE L06K8R7DQK) Image: Starch GLVCOK8R7DQK) LUMINUM OXIDE (UNIE LM2606933) Image: Starch GLVCOK8R7DQK) Product Character: Score 2 pieces Solor blue (Light Blue) Score 2 pieces RoUND Size 7mm Iavor Imprint Cote 159:520 Sontains Imprint Cote 159:520 Packaging Marketing Start Date Marketing End Date NDC:10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Marketing Start Date Marketing End Date NDC:10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 11/18/2013 Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 11/18/2013 11/18/2013	STARCH, CORN (UN	II: O8232NY3SJ)			
DLE C BLUE NO. 2 (UNIE LOGE KBR7DQ K) LUMINUM O XIDE (UNIE LM2606933) Product Characteristics Product Characteristics Product Characteristics Product Blue) ROUND	ACACIA (UNII: 5C540	3N26O)			
LUMINUM O XIDE (UNII: LMI2606933) Product Characteristics Color blue (Light Blue) Score 2 pieces hape ROUND Size 7mm Imprint Code JSP;520 Ontains UPProduct Of Package Description Marketing Start Date Marketing End Date NDC:10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 11/18/2013 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021210 Marketing Start Date Marketing Start Date Marketing End Date NDA NDA021210 KEVOTHYROSUNE SODIUM	SO DIUM STARCH G	LYCOLATE TYPE A POTATO (UNII:	5856J3G2A2)		
Product Characteristics Solor blue (Light Blue) Score 2 pieces hape ROUND Size 7mm Tavor JSP;520 Sontains JSP;520 Sontains JSP;520 Package Description Marketing Start Date NDC: 10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination NDC: 10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination NDC: 10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination NDC: 10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination NDC: 10544-266- 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination NDC: 10544-266- NOT Product JUNE ADDITE Marketing Information Number or Monograph Ciation Marketing Start Date Marketing Start Date Marketing End Date NDA021210 11/18/2013	FD&C BLUE NO.2 (UNII: L06K8R7DQK)			
inder blue (Light Blue) Score 2 pieces ROUND Size 7mm lavor Imprint JSP;520 contains Same Same Packaging Same Same Package Description Marketing Start Date NDC:10544-266- Site Same Same Same Same Same Same Marketing Start Date Marketing End Date Same Same Same Same Same Same <	ALUMINUM O XIDE ((UNII: LMI26O6933)			
inder blue (Light Blue) Score 2 pieces ROUND Size 7mm lavor Imprint JSP;520 contains Same Same Packaging Same Same Package Description Marketing Start Date NDC:10544-266- Site Same Same Same Same Same Same Marketing Start Date Marketing End Date Same Same Same Same Same Same <					
inder blue (Light Blue) Score 2 pieces ROUND Size 7mm lavor Imprint JSP;520 contains Imprint Severee veree Severee Severee Package Description NDC:10544-266- So in 1 BOTTLE, PLASTIC; Type 0: Not a Combined Marketing Start Marketing End Date Severee					
Image: Problem Size 7mm Image: Problem Image: Problem 38,520 Image: Problem Image: Problem Second and and and and and and and and and a	Product Charact	teristics			
Inprint Inprinprint Inprint Inprint Inprint Inprint Inp	Color	blue (Light Blue)	Score		2 pieces
Item Code Markage Description Marketing Start Date Marketing Start Date NDC:10544-266-30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/18/2013 Marketing Start Date Marketing End Date NDC:10544-266-30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/18/2013 Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA021210 11/18/2013 Marketing Start Date Marketing End Date USUAL SODIUM SODIUM SOUNDAL Marketing Start Date Marketing End Date	Shape	ROUND	Size		7mm
Ackaging Marketing Start Date Marketing End Date NDC:10544-266- 30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/18/2013 11/18/2013 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 11/18/2013 11/18/2013	Flavor		Imprint C	Code	JSP;520
Item Code Package Description Marketing Start Date Marketing End Date NDC:10544-266- 30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 11/18/2013 11/18/2013 Marketing Information NDA021210 Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 Marketing End Date	Contains				
Item Code Package Description Marketing Start Date Marketing End Date NDC:10544-266- 30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 11/18/20 13 11/18/20 13 Marketing Information NDA021210 Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/20 13 Marketing End Date					
Item Code Package Description Marketing Start Date Marketing End Date NDC:10544-266- 30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination 11/18/2013 11/18/2013 Marketing Information NDA021210 Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 Marketing End Date					
Itelin Code Package Description Date Date NDC:10544-266- 30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/18/2013	Packaging				
NDC:10544-266- 30 30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/18/2013 Marketing Information Marketing Category Application Number or Monograph Citation NDA021210 Marketing Start Date 11/18/2013 Marketing End Date EVOTTHYROUTH SODIUM South Start Start South Start South Start South Start South Start	# Itom Codo	Dackage Descrip	tion	Marketing Start	Marketing End
30 Product II/18/2013 Marketing Info/2013 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 II/18/2013	# Item Code	Package Descrip		Date	Date
Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 11/18/2013	1 NDC:10544-266-		ot a Combination	11/18/2013	
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 11/18/2013 IEVOTHYROXINE SODIUM IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	30	Product			
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 11/18/2013 IEVOTHYROXINE SODIUM IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII					
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date IDA NDA021210 11/18/2013 11/18/2013 IEVOTHYROXINE SODIUM IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII					
IDA NDA021210 11/18/2013	Marketing In	formation			
EVOTHYROXINE SODIUM	Marketing Catego	ry Application Number or Mono	ograph Citation	Marketing Start Date	Marketing End Dat
	NDA	NDA021210	1	11/18/2013	
	LEVOTHYRC	XINE SODIUM			
		ווו נמטופנ			

Product Information			
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:10544-258(NDC:0527-1344)
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	.088 mg

	ents							
8		Ingredi	ient Name					Strength
L ACTOSE (UNII: J2B2	2A4N98G)	0						0
		Ε ΤΥΡΕ Α ΡΟΤΑΤΟ (Ι	JNII: 5856J3G2A2)					
SILICON DIO XIDE (U								
ACACIA (UNII: 5C540)	3N26O)							
CELLULOSE, MICRO	OCRYSTAL	LINE (UNII: OP1R32D	6 1U)					
TARCH, CORN (UNI	II: 08232NY	/3SJ)						
D&C RED NO.40 (U	JNII: WZB91	127XOA)						
D&C BLUE NO. 2 (U	JNII: L06K8	R7DQK)						
LUMINUM O XIDE (UNII: LMI26	O6933)						
MAGNESIUM STEAR	ATE (UNII:	70097M6I30)						
Product Charact	eristics							
Color	I	purple	Score				2 pieces	
Shape	1	ROUND	Size				7mm	
Flavor			Imprint Code		JSP;515			
Contains								
Contains								
Contains								
					Manlassia		Ma	ulu din a Tradi
Packaging		Package Desc	cription		Marke tin Dat	•	Ma	rketing End Date
Packaging # Item Code NDC:10544-258-		Package Desc ITLE, PLASTIC; Type (-			•	Ma	
Packaging # Item Code	30 in 1 BOT Product		-		Dat	•	Ma	
Packaging # Item Code NDC:10544-258-			-		Dat	•	Ma	
Jackaging Item Code NDC:10544-258- 30	Product	ΓTLE, PLASTIC; Type (-	1	Dat	•	Ма	
Fackaging Item Code NDC:10544-258- 30	Product	ΓTLE, PLASTIC; Type (-		Dat	•	Ma	
Packaging I Item Code NDC:10544-258- 30	Product f ormati	ΓTLE, PLASTIC; Type (D: Not a Combination		Dat	e		Date
Packaging Item Code NDC:10544-258- 30 Marketing Information Marketing Categor	Product f ormati	TTLE, PLASTIC; Type (ON ication Number or N	D: Not a Combination	n M	Dat	e		
Packaging Item Code Image: NDC:10544-258-30 Marketing Information Informatio	Product formations y Appl	TTLE, PLASTIC; Type (ON ication Number or N	D: Not a Combination	n M	Dat 12/31/2013 Iarketing Sta	e		Date
Packaging # Item Code 1 NDC:10544-258- 30 Marketing Inf Marketing Categor	Product formations y Appl	TTLE, PLASTIC; Type (ON ication Number or N	D: Not a Combination	n M	Dat 12/31/2013 Iarketing Sta	e		Date
Packaging Item Code Indext Interpretent NDC:10544-258-30 Marketing Information Marketing Categor NDA	Product formations ry Appl NDA02	TTLE, PLASTIC; Type (ON ication Number or N 1210	D: Not a Combination	n M	Dat 12/31/2013 Iarketing Sta	e		Date
Packaging Item Code I NDC:10544-258- 30 IMarketing Inf Marketing Categor NDA IEVOTHYRO	Product formation ry Appl NDA022	TTLE, PLASTIC; Type (ON ication Number or N 1210	D: Not a Combination	n M	Dat 12/31/2013 Iarketing Sta	e		Date
Packaging Item Code Indext Interpretent NDC:10544-258-30 Marketing Information Marketing Categor NDA	Product formation ry Appl NDA022	TTLE, PLASTIC; Type (ON ication Number or N 1210	D: Not a Combination	n M	Dat 12/31/2013 Iarketing Sta	e		Date
Fackaging Item Code Item Code NDC:10544-258- Image: Strain of the	Product formation (y Appl NDA02: NDA02: MTAD2: NDA02: N	TTLE, PLASTIC; Type (ON ication Number or N 1210	D: Not a Combination	n M	Dat 12/31/2013 Iarketing Sta	e		Date

Active Ingredient/Active Moiety					
Ingredient Name	Basis of Strength	Strength			
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	.112 mg			

ORAL

Route of Administration

Inactive Ingred	lionts						
macuve mgret	lients	T.	nguadiant Nama			Strongth	
			ngredient Name			Strength	
CELLULOSE, MIC			P1R32D610)				
FD&C YELLOW N	•	,					
ALUMINUM OXIDI LACTOSE (UNII: J2	,						
	,						
MAGNESIUM STEA STARCH, CORN (U							
			' ATO (UNII: 5856J3G2A2)				
			AIO (UNII. 56565562A2)				
D&C YELLOW NO SILICON DIOXIDE							
ACACIA (UNII: 5C54		50AD04J					
	10011200)						
Product Chara	- 4						
	cteristics	n	_		- ·		
Color		yello w	Score		2 piece	S	
Shape		ROUND	Size			7mm	
Flavor			Imprint Code		JSP;516	6	
Contains							
Packaging							
# Item Code		Packag	e Description	Marketing S Date	Start N	farketing End Date	
1 NDC:10544-261- 30	30 in 1 BO Product	TTLE, PLASTIC;	; Type 0: Not a Combination	0 1/0 2/20 14			
Marketing I	nformat	ion					
Marketing I Marketing Categ			er or Monograph Citation	Marketing Start	Date Mar	keting End Dat	

Labeler - Blenheim Pharmacal, Inc. (171434587)

Registrant - Blenheim Pharmacal, Inc. (171434587)

Establishment

Name	Address	ID/FEI	Business Operations
Blenheim Pharmacal, Inc.		171434587	repack(10544-229, 10544-228, 10544-247, 10544-260, 10544-262, 10544-264, 10544-258, 10544-261), relabel(10544-266)

Revised: 3/2015

Blenheim Pharmacal, Inc.